Hypotensive therapy of arterial hypertension in chronic limb ischemia and acute thrombotic occlusion
https://doi.org/10.52420/2071-5943-2022-21-4-93-100
Abstract
The aim of the investigation was to evaluate the efficacy and safety of the treatment of arterial hypertension syndrome in patients with peripheral arterial disease of the lower and upper extremities and to analyze the efficiency of the effect of operative revascularization of the limb arteries on the course of arterial hypertension. Materials and methods. Literature sources were searched for 15 years in electronic resources of Pubmed. com, Sciencedirect.com, eLibrary.ru. Results and discussion. Hypotensive therapy, in patients with peripheral arterial disease and local "atherothrombotic" mechanisms of acute thrombotic occlusion, the main groups of drugs providing metabolic safety of long-term treatment can significantly affect the risk of repeated arterial thrombosis and critical ischemia, including, after reconstructive vascular surgery. International methodological materials and recommendations practically do not cover the issues of perspective hypotensive therapy of patients with embolic character of acute arterial occlusion in chronic lower limb ischemia. These categories of patients were not singled out separately in the controlled prospective studies, therefore, planning of additional works on the study of the issue is required. Conclusion. Adequately selected hypotensive therapy and blood pressure control in patients with lower limb peripheral atherosclerosis allows not only to provide the target level of blood pressure reduction, but also to reduce the risk of thrombotic complications, including those leading to critical limb ischemia and gangrene.
About the Authors
N. V. Teplova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Natalija V. Teplova – Doctor of medicine
Moscow
V. I. Vechorko
Municipal Clinical Hospital No. 15 named after O.M. Filatov
Russian Federation
Russian Federation
Valerij I. Vechorko – MD
Moscow
K. I. Bairova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Kermen I. Bairova – MD
Moscow
E. I. Evsikov
Pirogov Russian National Research Medical University;
Municipal Clinical Hospital No. 15 named after O.M. Filatov
Russian Federation
Russian Federation
Evgenij I. Evsikov – Doctor of medicine
Moscow
https://orcid.org/0000-0002-1448-9077
M. Kh. Zhapueva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Mareta Kh. Zhapueva – Postgraduate student
Moscow
A. G. Dzheksembekov
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Ajdar G. Dzheksembekov – Postgraduate student
Moscow
References
1. Firnhaber JM, Powell CS. Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment. Am Fam Physician. 2019 Mar 15;99(6):362–369.
2. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the preventionof cardiovascular disease: meta-analysis of 147 randomised trials in the context ofexpectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
3. Sigvant B, Wiberg-Hed man K, Bergqist D, Rolandsson O, Andersson B, Persson E, Wablberg E. A population-based study of peripheral arteral disease prevalence with special focus on critical limb ischemia and sex differences. J. Vasc. Surgery.2007;45:1185–1191.
4. Brevetti J, Oliva G, Silvestro A, Scopacasa F, Chiariello M. Prevalence, risk factors and cardiovascular comorbidity of symptomatic peripheral arterial disease in Italy. Atherosclerosis. 2004;175:131–138.
5. Guidelines for the Management of Patients with Peripheral Arterial Disease, Management of Peripheral Arterial Disease (PAD). TransAtlantic Inter-Society Consensus (TASC), 2007. J Vasc Surg. 2007 Jan;45 Suppl S:S5–67.
6. The TASC Steering Committee. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Endovasc Ther. 2015;22:657–671.
7. National guidelines for management of patients with vascular artery pathology (Rusian consensus document). Part 1: peripheralartery. Ed. Bakulev national surgery centre. 2010. Russian. Moscow. 87 р.
8. Lyusov V.A., Evsikov E.M., Teplova N.V. Etiology and factors of development and progression of severe and malignant arterial hypertension. Russian journal of cardiology. 2009;4(14):6–16.
9. Rosamond W, Flegal K, Furie K [et al]. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:25–146.
10. Guidelines on the diagnosis and treatment of periferal artery diseases. Eur. Heart. J. 2011;32:2851–2906.
11. Putilina M.V. The role of endothelial dysfunction in cerebrovascular diseases Doctor. 2012,7:24–28
12. Guidelines on the diagnosis and treatment of periferal artery diseases. Eur. Heart. J. 2011;32:2851–2906.
13. 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology. American Heart Association. Task Force on Clinical Practice. Guidelines. GerhardHerman MD, Gornik HL, Barrett C, Barshes NR [et al]. Circulation. 2017 Mar 21;135(12):e726–e779.
14. Piller LB, Simpson LM, Baraniuk S, Habib GB, Rahman M, Basile JN, Dart RA, Ellsworth AJ, Fendley H, Probstfield JL, Whelton PK, Davis BR; Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. ALLHAT Collaborative. J Gen Intern Med. 2014 Nov;29(11):1475–83.
15. Itoga NK, Tawfik DS, Lee CK, Maruyama S, Leeper NJ, Chang TI. Association of Blood Pressure Measurements with Peripheral Artery Disease Events. Circulation. 2018 Oct 23;138(17):1805–1814.
16. Lyusov V.A., Evsikov E.M., Teplova N.V. Etiology and factors of development and progression of severe and malignant arterial hypertension. Russian journal of cardiology. 2009;4(14):6–16.
17. Evsikov E.M, Teplova N.V. Pharmacoeconomic efficiency of a new generic atorvastatin drug Tulip- in patients with hyperlipidemia. 2006;14(2):122–126.
18. Teplova N.V. Vasilip in the treatment of atherosclerosis and hyperlipidemia in breast cancer, 2005;13(2):94–96.
19. Vogel TR, Smith JB, Kruse RL. Hospital readmissions after elective lower extremity vascular procedures. Vascular. 2018 Jun;26(3):250–261.
20. 2018 ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) Russian Journal of Cardiology. 2018;23(12):143–228.
21. National guidelines for management of patients with vascular artery pathology (Rusian consensus document). Part 1: peripheralartery. Ed. Bakulev national surgery centre. 2010. Russian. Moscow.
22. Putilina M.V., Teplova N.V. Drug safety as a priority area of domestic medicine. Medical business. 2019;4:7–14 DOI: 10.24411/2071-5315-2019-12152.
23. Putilina M.V. Combined neuroprotective therapy in cerebrovascular diseases. Doctor. 2012;4:69–73.
24. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
25. Korhonen PE, Kautiainen H, Kantola I. Patients with resistant hypertension have more peripheral arterial disease than other uncontrolled hypertensives. J Hum Hypertens. 2015 Jan;29(1):46–9.
26. Weber T, Arbeiter K, Ardelt F, Auer J, Aufricht C [et al]. Austrian Consensus on High Blood Pressure 2019. Wien Klin Wochenschr. 2019 Nov;131(Suppl 6):489–590.
27. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA [et al]. Association of systolic blood pressure with macrovascular and microvascular complications of typediabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–419.
28. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl. J Med. 2000;342:145–153.
29. Bodewes TCF, Darling JD, O'Donnell TFX, Deery SE, Shean KE, Mittleman MA, Moll FL, Schermerhorn ML. Long-term mortality benefit of renin-angiotensin system inhibitors in patients with chronic limb-threatening ischemia undergoing vascular intervention. J Vasc Surg. 2018 Mar;67(3):800–808.
30. Putilina M.V., Soldatov M. Cerebral strokes in old age. Features of the clinical picture, course, treatment. Doctor. 2006;5:29–34.
31. Teplova N.V., Evsikov E.M. Angiotensin receptor blocker Valsartan (Diovan) in clinical practice. 2005;14:944.
32. Ong KT, Delerme S, Pannier B, Safar ME, Benetos A, Laurent S, Boutouyrie P. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens. 2011;29:1034–1042.
33. Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomized controlled trials. Atherosclerosis. 2012;221:18–33.
34. Karalliedde J, Smith A, De Angelis L, Mirenda V, Kandra A, Botha J. Ferber P, Viberti G. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension. 2008;51:1617–1623.
35. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588–2605.
36. Saiki A, Sato Y, Watanabe R, Watanabe Y, Imamura H, Yamaguchi T, Ban N, Kawana H, Nagumo A, Nagayama D, Ohira M, Endo K, Tatsuno I. The Role of a Novel Arterial Stiffness Parameter, Cardio-Ankle Vascular Index (CAVI), as a Surrogate Marker for Cardiovascular Diseases. J Atheroscler Thromb. 2016;23(2):155–68.
37. Putilina M.V. Risk factors, features of clinical course and treatment approaches in aged patients with cerebral stroke .Korsakov Journal of Neurology and Psychiatry. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2011;111(5): 90–95.
38. Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013 Sep 11;2013(9):CD005508.
39. Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57:1122–1128.
40. Mirault T, Galloula A, Cambou JP, Lacroix P, Aboyans V, Boulon C, Constans J, Bura-Riviere A, Messas E. Impact of betablockers on general and local outcome in patients hospitalized for lower extremity peripheral artery disease: The COPART Registry. Medicine (Baltimore). 2017 Feb;96(5):e5916.
41. Putilina M.V., Teplova N.V. Rational therapy algorithms for chronic cerebral ischemia. Clinical guidelines. Zhur. Nervous diseases. 2019;1:11–16.
42. Teplova N.V., Lyusov V.N., Oganov R.G., Evsikov E.M., Sharipov R.A. Nephrogenic factors of resistance formation to antihypertensive therapy in patients with primary arterial hypertension; Rational pharmacotherapy in cardiology. 2015; 6(11):590–594.
43. Putilina M.V., Fedin A.I. Post-stroke depression, the possibilities of therapy in patients in the acute period of stroke. Atmosphere. Nervous diseases. 2005;1:6–9.
44. Bediako-Bowan AA, Adjei GO, Clegg-Lamptey JN, Naaeder SB. The burden and characteristics of peripheral arterial disease in patients undergoing amputation in Korle Bu Teaching Hospital, Accra, Ghana. Ghana Med J. 2017 Sep;51(3):108–114.
Review
For citations:
Teplova NV, Vechorko VI, Bairova KI, Evsikov EI, Zhapueva MK, Dzheksembekov AG. Hypotensive therapy of arterial hypertension in chronic limb ischemia and acute thrombotic occlusion. Ural Medical Journal. 2022;21(4):93-100. (In Russ.) https://doi.org/10.52420/2071-5943-2022-21-4-93-100
Views:
209
Email this article 